Background: Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of lung adenocarcinoma. The recent association of four oncogenic driver genes, ALK, ROS1, RET, and NTRK1, as lung tumor predictive biomarkers has increased the need for development of up-to-date technologies for detection of these biomarkers in limited amounts of material. Methods: We describe here a multi-institutional study using the Ion AmpliSeq™ RNA Fusion Lung Cancer Research Panel to interrogate previously characterized lung tumor samples. Results: Reproducibility between laboratories using diluted fusion-positive cell lines was 100%. A cohort of lung clinical research samples from different origins (tissue biopsies, tissue re...
Aim: ALK, ROS1, NTRK and RET gene fusions and MET exon 14 skipping alterations represent novel ...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
Precision medicine requires accurate multi-gene clinical diagnostics. We describe the implementation...
Background: Gene fusion events resulting from chromosomal rearrangements play an important role in i...
Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of...
IntroductionROS1 and RET gene fusions were recently discovered in non–small-cell lung cancer (NSCLC)...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
BACKGROUND: Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyros...
AbstractIntroductionFusions of the anaplastic lymphoma receptor tyrosine kinase gene (ALK), ret prot...
Approximately 7% of non-small cell lung carcinomas (NSCLCs) harbor oncogenic fusions involving ALK, ...
AbstractWhether Cell block (CB) samples are applicable to detect anaplastic lymphoma kinase (ALK), c...
Introduction: Gene fusions are frequent chromosomal aberrations in solid tumors. In Lung cancer (LC)...
OBJECTIVES: There is an increasing number of driver fusions in NSCLC which are amenable to targeted ...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
Targeted therapy in lung cancer requires the assessment of multiple oncogenic driver alterations, in...
Aim: ALK, ROS1, NTRK and RET gene fusions and MET exon 14 skipping alterations represent novel ...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
Precision medicine requires accurate multi-gene clinical diagnostics. We describe the implementation...
Background: Gene fusion events resulting from chromosomal rearrangements play an important role in i...
Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of...
IntroductionROS1 and RET gene fusions were recently discovered in non–small-cell lung cancer (NSCLC)...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
BACKGROUND: Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyros...
AbstractIntroductionFusions of the anaplastic lymphoma receptor tyrosine kinase gene (ALK), ret prot...
Approximately 7% of non-small cell lung carcinomas (NSCLCs) harbor oncogenic fusions involving ALK, ...
AbstractWhether Cell block (CB) samples are applicable to detect anaplastic lymphoma kinase (ALK), c...
Introduction: Gene fusions are frequent chromosomal aberrations in solid tumors. In Lung cancer (LC)...
OBJECTIVES: There is an increasing number of driver fusions in NSCLC which are amenable to targeted ...
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver event...
Targeted therapy in lung cancer requires the assessment of multiple oncogenic driver alterations, in...
Aim: ALK, ROS1, NTRK and RET gene fusions and MET exon 14 skipping alterations represent novel ...
ALK, ROS1 and RET gene fusions are important predictive biomarkers for tyrosine kinase inhibitors in...
Precision medicine requires accurate multi-gene clinical diagnostics. We describe the implementation...